Buy or sell Sagimet Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Sagimet Biosciences Stock

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.

About Sagimet Biosciences Stock

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.

Funding History

May 2007$7.6M
July 2009$30.0M
January 2012$20.0M
October 2012$8.1M
June 2013$20.0M
December 2014$28.5M
July 2016$5.4M
February 2019$18.0M
August 2019$7.0M
December 2020$69.0M
February 2021$80.0M

Management

Member of the Board of Directors

Beth Seidenberg

CEO

George Kemble

Board Member

Matthew McAviney

Board Member

Ari Helenius

Chairman

David Mott

Co-Founder

Urs Greber

Member of the Board of Directors

Richard Klausner

Co-Founder

Lucas Pelkmans

Board Member

James F. Young

Board Member

Robert Garland

Chief Scientific Officer

George Kemble

CFO and Head Corporate Development

Dennis Hom

Investor

Sara Nayeem

Board Member

Gordon Ringold

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo